BIORETEC OY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.88 EUR | 0.00% |
|
+0.35% | +20.00% |
| 28/06 | Bioretec Flags Delay in Receipt of European CE Mark for Trauma Screw | MT |
| 19/06 | Bioretec Ltd. Reports Successful Clinical Outcomes from U.S. Controlled Launch of RemeOs Trauma Screw | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 19.83 | 46.89 | 58.57 | 58.57 | - |
| Enterprise Value (EV) 1 | 19.83 | 46.89 | 58.57 | 57.22 | 59.77 |
| P/E ratio | -3.27 x | -14.1 x | -15.2 x | -16.5 x | -32 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 15.9 x | 15 x | 10.8 x | 5.69 x |
| EV / Revenue | - | 15.9 x | 15 x | 10.6 x | 5.8 x |
| EV / EBITDA | - | -22.2 x | -20.7 x | -16.6 x | -54.3 x |
| EV / FCF | - | -17.9 x | -15.5 x | -14 x | -37.4 x |
| FCF Yield | - | -5.59% | -6.44% | -7.17% | -2.68% |
| Price to Book | - | 24.5 x | 8.73 x | 14.4 x | 25 x |
| Nbr of stocks (in thousands) | 14,112 | 19,537 | 20,337 | 20,337 | - |
| Reference price 2 | 1.405 | 2.400 | 2.880 | 2.880 | 2.880 |
| Announcement Date | 17/02/22 | 17/02/23 | 16/02/24 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales 1 | - | 2.942 | 3.906 | 5.4 | 10.3 |
| EBITDA 1 | - | -2.112 | -2.833 | -3.45 | -1.1 |
| EBIT 1 | - | -2.292 | -3.034 | -3.65 | -1.65 |
| Operating Margin | - | -77.91% | -77.68% | -67.59% | -16.02% |
| Earnings before Tax (EBT) 1 | - | -2.415 | -3.788 | -3.8 | -1.8 |
| Net income 1 | -6.017 | -2.416 | -3.789 | -3.8 | -1.8 |
| Net margin | - | -82.12% | -97% | -70.37% | -17.48% |
| EPS 2 | -0.4300 | -0.1700 | -0.1900 | -0.1750 | -0.0900 |
| Free Cash Flow 1 | - | -2.62 | -3.4 | -4.1 | -1.6 |
| FCF margin | - | -89.06% | -85% | -75.93% | -15.53% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 17/02/22 | 17/02/23 | 16/02/24 | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 1.2 |
| Net Cash position 1 | - | - | 5.8 | 1.35 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -1.091 x |
| Free Cash Flow 1 | - | -2.62 | -3.4 | -4.1 | -1.6 |
| ROE (net income / shareholders' equity) | - | -77.2% | -68.8% | -59.8% | -54% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share 2 | - | 0.1000 | 0.3300 | 0.2000 | 0.1200 |
| Cash Flow per Share 2 | - | -0.1200 | -0.1200 | -0.1800 | -0.0600 |
| Capex 1 | - | 0.26 | 0.35 | 0.45 | 0.75 |
| Capex / Sales | - | 8.85% | 8.75% | 8.33% | 7.28% |
| Announcement Date | 17/02/22 | 17/02/23 | 16/02/24 | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.88
EUR
Average target price
3.85
EUR
Spread / Average Target
+33.68%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +20.00% | 62.7M | |
| +75.69% | 12.57B | |
| +7.45% | 6.98B | |
| -28.45% | 6.78B | |
| -19.73% | 4.59B | |
| +17.40% | 4.15B | |
| -21.37% | 3.83B | |
| -25.83% | 2.73B | |
| -1.24% | 2B | |
| +14.74% | 1.9B |
- Stock Market
- Equities
- BRETEC Stock
- Financials Bioretec Oy
